Dr. Sylvia Kurz, MD
Claim this profileLaura and Isaac Perlmutter Cancer Center at NYU Langone
Studies Brain Tumor
Studies Solid Tumors
8 reported clinical trials
11 drugs studied
Area of expertise
1Brain Tumor
H3 K27M positive
histone H3
IHC
2Solid Tumors
MET negative
IDH negative
Affiliated Hospitals
Clinical Trials Sylvia Kurz, MD is currently running
ONC201
for Brain Tumor
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.
Recruiting1 award Phase 3
AB154 + AB122
for Glioblastoma
This is a phase 0/I exploratory study. Patients at first or second recurrence of glioblastoma will be enrolled. The study will be divided into two cohorts: Cohort A (safety cohort) and Cohort B (surgical patient cohort). Cohort A: Eligible patients will be sequentially enrolled to receive intravenous domvanalimab combined with zimberelimab (N=6). Domvanalimab will be given at a dose of 10 mg/kg and zimberelimab will be given at a dose of 240 mg (flat). The dosing was determined in a separate study in solid tumors; this cohort will confirm the safety of the dosing schedule in patients with brain tumors. Cohort B: Expansion surgical cohort. The purpose of cohort B is to provide an additional safety evaluation of domvanalimab + zimberelimab as well as tissue and blood for exploratory ancillary studies investigating the effects of domvanalimab + zimberelimab in the tumor and tumor microenvironment. A total of 46 patients will be enrolled in this cohort.
Recruiting0 awards Phase < 13 criteria
More about Sylvia Kurz, MD
Clinical Trial Related7 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Sylvia Kurz, MD has experience with
- Nivolumab
- Ipilimumab
- ONC201
- Vemurafenib
- Cobimetinib
- Stereotactic Radiosurgery
Breakdown of trials Sylvia Kurz, MD has run
Brain Tumor
Solid Tumors
Glioblastoma
Mesial Temporal Sclerosis
Craniopharyngioma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Sylvia Kurz, MD specialize in?
Sylvia Kurz, MD focuses on Brain Tumor and Solid Tumors. In particular, much of their work with Brain Tumor has involved H3 K27M positive patients, or patients who are histone H3.
Is Sylvia Kurz, MD currently recruiting for clinical trials?
Yes, Sylvia Kurz, MD is currently recruiting for 3 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Sylvia Kurz, MD has studied deeply?
Yes, Sylvia Kurz, MD has studied treatments such as Nivolumab, Ipilimumab, ONC201.
What is the best way to schedule an appointment with Sylvia Kurz, MD?
Apply for one of the trials that Sylvia Kurz, MD is conducting.
What is the office address of Sylvia Kurz, MD?
The office of Sylvia Kurz, MD is located at: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York 10016 United States. This is the address for their practice at the Laura and Isaac Perlmutter Cancer Center at NYU Langone.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.